Cargando…

Complete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumor

INTRODUCTION: Gastrointestinal stromal tumors (GIST) are the most frequent mesenchymal tumors of the digestive tract. Extraintestinal locations (EGIST) have been described showing similar pattern of immunohistochemical markers than GIST. Inhibitors of tyrosine kinases such as Imatinib or Sunitinib a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Quezada, Nicolás, Acevedo, Francisco, Marambio, Andrés, León, Felipe, Galindo, Hector, Roa, Juan Carlos, Jarufe, Nicolás
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4189531/ https://www.ncbi.nlm.nih.gov/pubmed/25194604 http://dx.doi.org/10.1016/j.ijscr.2014.05.009

Ejemplares similares

Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008)

ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor
por: Rink, Lori, et al.
Publicado: (2013)

Optimal Duration of Imatinib Mesylate Therapy in Metastatic Gastrointestinal Stromal Tumours
por: Gauden, Ruth, et al.
Publicado: (2011)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
por: Ksienski, Doran
Publicado: (2011)

Recurrent Gastrointestinal Stromal Tumors in the Imatinib Mesylate Era: Treatment Strategies for an Incurable Disease
por: Platoff, Rebecca M., et al.
Publicado: (2017)

Pathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report
por: El Mesbahi, Omar, et al.
Publicado: (2011)

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: Case report
por: Hughes, Brett, et al.
Publicado: (2004)

Efficacy of Imatinib Mesylate Neoadjuvant Treatment for a Locally Advanced Rectal Gastrointestinal Stromal Tumor
por: Yoon, Kyu Jong, et al.
Publicado: (2011)

Gynecomastia during imatinib mesylate treatment for gastrointestinal stromal tumor: a rare adverse event
por: Liu, HeLi, et al.
Publicado: (2011)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

Establishment of a GIST-T1 gastrointestinal stromal tumour cell line resistant to imatinib mesylate
por: Zhou, Yongjian, et al.
Publicado: (2018)

The Merendino procedure following preoperative imatinib mesylate for locally advanced gastrointestinal stromal tumor of the esophagogastric junction
por: Staiger, Wilko I, et al.
Publicado: (2008)

Concurrent Male Gynecomastia and Testicular Hydrocele after Imatinib Mesylate Treatment of a Gastrointestinal Stromal Tumor
por: Kim, Hawk, et al.
Publicado: (2005)

Imatinib Mesylate for Patients With Unresectable or Recurrent Gastrointestinal Stromal Tumors: 10-Year Experience From Vietnam
por: Hung, Kien Do, et al.
Publicado: (2019)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate
por: Sawaki, Akira, et al.
Publicado: (2009)

Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving Imatinib Mesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor
por: Agaimy, Abbas, et al.
Publicado: (2013)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Management of Skin Toxicity Related to the Use of Imatinib Mesylate (STI571, Glivec™) for Advanced Stage Gastrointestinal Stromal Tumours
por: Scott, Lucy C., et al.
Publicado: (2005)

Prolonged Therapy with Imatinib Mesylate before Surgery for Advanced Gastrointestinal Stromal Tumor Results of a Phase II Trial
por: Doyon, C., et al.
Publicado: (2012)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
por: Chen, Yan, et al.
Publicado: (2020)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate
por: Goerres, G. W., et al.
Publicado: (2004)

Transsacral excision with pre-operative imatinib mesylate treatment and approach for gastrointestinal stromal tumors in the rectum: A report of two cases
por: SUN, LI-FENG, et al.
Publicado: (2014)

Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report
por: Jiang, Meng-jie, et al.
Publicado: (2015)

Tumour Lysis Syndrome Occurring in a Patient with Metastatic Gastrointestinal Stromal Tumour Treated with Glivec (Imatinib Mesylate, Gleevec, STI571)
por: Pinder, Elizabeth M., et al.
Publicado: (2007)

A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome
por: Zhu, Jiang, et al.
Publicado: (2010)

What is the appropriate duration of adjuvant imatinib mesylate treatment for primary gastrointestinal stromal tumors classified according to the strict definition of tumor rupture?
por: Lu, Jun, et al.
Publicado: (2019)

Primary Prostatic Extra-Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate as Neoadjuvant and Adjuvant Therapy: A Case Report and Literature Review
por: Shen, Haixiang, et al.
Publicado: (2019)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Imatinib mesylate resistance and mutations: An Indian experience
por: Srivastava, Shweta, et al.
Publicado: (2013)

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

The teratogenic effects of imatinib mesylate on rat fetuses
por: El Gendy, M.M., et al.
Publicado: (2015)

Exacerbation of Psoriasis after Imatinib Mesylate Treatment
por: Shim, Joon Ho, et al.
Publicado: (2016)

In vitro inhibitory effects of imatinib mesylate on stromal cells and hematopoietic progenitors from bone marrow
por: Soares, P.B., et al.
Publicado: (2012)

Complete remission of a periorbital dermatofibrosarcoma protuberans with adjuvant imatinib mesylate in a child
por: Yen, Hsi, et al.
Publicado: (2015)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Plantar Keratoderma with Pachyonychia Likely Induced by Imatinib Mesylate
por: Kim, Hyung Ok, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cifim9o7da6qug83ru54mqqjpb